Soil-transmitted helminth infections among migrants and travelers: a 10-year retrospective study Authors: Izar Blazquez-Bermejo, Fernando Salvador, Elena Sulleiro, Núria Serre-Delcor, Joan Martínez-Campreciós, Maria Luisa Aznar, Pau Bosch-Nicolau, Diana Pou, Sol M San José-Villar, Inés Oliveira-Souto, Israel Molina Published: 2026 ABSTRACT AbstractBackgroundSoil-transmitted helminth (STH) infections, caused by Ascaris lumbricoides, Trichuris trichiura, and hookworms, are widely distributed in tropical regions and significantly contribute to morbidity and mortality. These parasites share similar life cycles, and treatment is primarily based on benzimidazoles. This study aims to describe the clinical and epidemiological characteristics of STH cases among migrants and travelers who attended the Vall d’Hebron-Drassanes International Health Unit between 2014 and 2024, the treatments administered, and their efficacy.MethodsThis retrospective descriptive study reviewed STH cases associated with migration or travel during the period 2014–2024. Diagnosis was established either through identification of eggs or larvae in stool samples or through the detection of adult Ascaris lumbricoides worms in digestive samples, always associated with a migratory process or international travel. Clinical and epidemiological data were collected and analyzed using SPSS.ResultsA total of 361 STH cases were identified, with a mean age of 32 years. Of these, 77% were migrants, 15.7% were travelers visiting friends and relatives (VFR), and 7.2% were travelers. Hookworm infection was diagnosed in 126 cases, Trichuris trichiura in 113 cases, Ascaris lumbricoides in 87 cases, and 35 patients presented with multiple STH infections. Forty-six (12.7%) were symptomatic, predominantly with gastrointestinal symptoms, and 38% presented with eosinophilia. Ninety-five percent of patients received benzimidazole-based treatment, and therapeutic failure was observed in 7.8% of cases. Cure rates were highest for A. lumbricoides (nearly 100%) and remained above 90% for T. trichiura, whereas hookworm infections showed lower rates, ranging from 83% with albendazole to 92% with mebendazole. Multiple STH infections showed, proportionally, higher rates of therapeutic failure.ConclusionsMost STH cases were diagnosed in asymptomatic migrants and VFRs, highlighting the importance of screening for imported diseases in migrant populations. The observed increase in therapeutic failure with commonly used regimens highlights the need to standardize treatment protocols and consider the incorporation of new drugs and combination therapies.Keywords: Soil-transmitted helminths, Migrants, Neglected tropical diseases, Benzimidazoles, Ivermectin Background Soil-transmitted helminth (STH) infections, caused by Ascaris lumbricoides, Trichuris trichiura, and the hookworms Necator americanus and Ancylostoma duodenale, are estimated to affect approximately 1.5 billion people worldwide, representing about 24% of the global population [1]. These infections are widely distributed, with higher prevalence in tropical and subtropical regions, such as Sub-Saharan Africa, South America, China, and Southeast Asia. Their survival and propagation are facilitated by warm climates and moist soils, while poverty and the lack of hygiene and sanitation favor infection [2, 3]. Consequently, they primarily affect vulnerable populations in low- and middle-income countries, particularly children and pregnant women [2–4]. Nevertheless, zoonotic helminth infections have also been reported in Europe [5]. Although a decline in STH prevalence has been observed in recent years, their impact in terms of Disability-Adjusted Life Years (DALYs) remains significant, with an estimated burden of 3.3 million DALYs. These infections are associated with adverse outcomes, such as prematurity, low birth weight, impaired growth and cognitive development, anemia, malnutrition, and intestinal malabsorption [1, 2, 6, 7]. Ascaris lumbricoides is the most prevalent soil-transmitted helminth, affecting approximately 804 million people, followed by T. trichiura (477 million) and hookworms (472 million). These parasites primarily affect children and adolescents [4]. Infection by A. lumbricoides and T. trichiura occurs through ingestion of eggs, whereas hookworm infection is acquired through skin penetration by larvae. Both A. lumbricoides and hookworms undergo a pulmonary migration phase, which can lead to eosinophilic pneumonia (Loeffler’s syndrome). In most cases, infections are asymptomatic; however, severe presentations may occur, such as acute abdomen (A. lumbricoides), rectal prolapse (T. trichiura), or anemia and/or eosinophilia in all three infections. Diagnosis is typically made by microscopic identification of eggs in stool samples and, less frequently, by detection of adult worms in stool or vomitus (A. lumbricoides) or larvae in stool (hookworms). Benzimidazoles and ivermectin are the main treatments for STH infections; however, the different regimens currently proposed are based largely on clinical experience, and there are no standardized recommendations regarding treatment dosage or duration. In recent years, an increase in therapeutic failures with commonly used regimens has been observed, suggesting the emergence of resistance mechanisms previously absent. This trend has led to growing scientific interest in the development and evaluation of new treatment strategies [2]. In our setting and within our healthcare area, although these infections are not endemic, their incidence is far from negligible, mainly due to migratory flows and international travel. Understanding the epidemiological and clinical profile of patients with soil-transmitted helminth infections, the temporal trend in diagnoses, as well as the most commonly used treatments and their outcomes, will improve clinical management and provide valuable information for the development of clinical guidelines. Methods Study design and population This is a descriptive, observational, single-center, retrospective study. We included patients with confirmed diagnoses of soil-transmitted helminthiasis, based on identification of eggs or larvae in stool samples using the Ritchie formalin–ether concentration technique, or detection of adult A. lumbricoides worms in other digestive samples, along with a documented association of the diagnosis with a migratory process or international travel. Patient records from the Vall d’Hebron-Drassanes International Health Unit in Barcelona were reviewed for the period between January 2014 and October 2024. Our center is a reference point for healthcare provision to migrant populations, often serving as the first point of contact with the health system. It plays an active role in screening for imported diseases and in providing care to travelers, both pre-travel and post-travel. Patients were managed according to the unit’s protocol for asymptomatic migrants, which includes a general blood test (complete blood count, basic biochemistry, and serologies for HIV, syphilis, hepatotropic viruses, and Strongyloides), chest X-ray, and stool examination using the Ritchie technique (one sample, three in cases of eosinophilia). Additional screening for Plasmodium spp., microfilariae, and schistosomiasis was performed in patients from Sub-Saharan Africa, and for Trypanosoma cruzi in those from Central and South America. For symptomatic patients, screening was performed based on geographical origin and presenting symptoms. Post-treatment follow-up included stool examination at least 1 month after therapy, although no predefined upper limit was established. Data were collected for epidemiological variables (age, sex, travel type, country of origin, country of infection), clinical variables (symptoms, comorbidities), diagnostic tests performed, other infections diagnosed, and treatment administered. Data availability varied across variables, and analyses were performed using available-case data. The number of observations is indicated where relevant. All patients were offered treatment according to routine clinical practice. For data analysis, eosinophilia was defined as an absolute eosinophil count > 500/μL, and anemia as hemoglobin < 13 g/dL in men and < 12 g/dL in women. Cure was defined as a negative stool examination (single sample) after treatment. Ethical considerations The procedures were carried out in accordance with the ethical standards set forth in the 2024 revision of the Declaration of Helsinki. The protocol for this study was approved by the Clinical Research Ethics Committee of Vall d'Hebron University Hospital (PR(AG) 222–2025). A waiver of written informed consent was warranted considering the retrospective nature of the study and the expected large number of records to be screened. Statistical analysis Patient data were entered into a database created using the REDCap platform and subsequently exported to the SPSS statistical package (Version 19.0; SPSS Inc, Chicago, IL, USA) for analysis. Qualitative variables were expressed as absolute numbers and percentages, while quantitative variables were expressed as mean and standard deviation (SD) or median and interquartile range (IQR). Categorical variables were compared using the chi-squared test or the Fisher’s exact test when appropriate. Continuous variables were compared using the Student’s t test or the Kruskal–Wallis test. The level of significance for all tests was set at p < 0.05. Results A total of 361 cases were analyzed. Of these, 60.4% were male, with a mean age of 32 (SD 16.8) years. Two hundred seventy-eight (77.01%) were migrants, 57 (15.79%) were travelers visiting friends and relatives (VFR), and 26 (7.2%) were travelers. Among migrants and VFR, patients were originally from or had recently traveled to Equatorial Guinea (114 individuals), Senegal (46), Pakistan (26), and Gambia (26) (Table 1). Migrants had been in Spain for an average of 3.3 (SD 3.3) months at the time of the visit. In the traveler group, mostly born in Spain (19 of 26, the remainder from other European countries), destinations varied widely, with no clear predominance, but mainly included Africa, South America, and Asia (Table 2). The mean duration of travel was 144 (SD 112) days for VFR and 139 (SD 131) days for other travelers. Table 1Country of birth of migrants and VFR travelers with STH infectionsContinent and country of birthn (%)Africa234 (69.8)Equatorial Guinea114 (34)Senegal46 (13.7)Gambia26 (7.8)Guinea-Conakry12 (3.6)Mali8 (2.4)Nigeria6 (1.8)Cameroon4 (1.2)Ivory Coast, Gabon, Ghana, Guinea-Bissau, Morocco, Democratic Republic of Congo2 (0.6)Algeria, Somalia, Togo1 (0.3)Asia57 (17)Pakistan26 (7.8)Bangladesh17 (5.1)Afghanistan, Philippines5 (1.5)India4 (1.2)South America and Caribbean43 (12.8)Bolivia17 (5.1)Honduras15 (4.5)Colombia, El Salvador2 (0.6)Brazil, Ecuador, Guatemala, Haiti, Nicaragua, Peru, Venezuela1 (0.3)Europe1 (0.3)Romania1 (0.3)Bold is the result of the sum of all the cases of the same continent Country of birth of migrants and VFR travelers with STH infections Bold is the result of the sum of all the cases of the same continent Table 2Destination countries of travelers with STH infectionsContinent and destination countryn (%)Africa9 (34.6)Congo3 (11.5)Democratic Republic of Congo2 (7.7)Cameroon, Morocco, Mozambique, São Tomé1 (3.8)Asia9 (34.6)India, Philippines, Indonesia2 (7.7)Thailand, Myanmar, United Arab Emirates,1 (3.8)South America and Caribbean7 (26.9)Brazil, Chile2 (7.7)Peru, Ecuador, Bolivia1 (3.8)Oceania1 (3.8)Tasmania1 (3.8)Bold is the result of the sum of all the cases of the same continent Destination countries of travelers with STH infections Bold is the result of the sum of all the cases of the same continent A progressive increase in the number of cases was observed between 2014 and 2019, except for 2018 (Fig. 1). In 2020, there was a marked decrease, followed by a slight increase over the next 2 years, and then another decline, remaining below pre-2020 levels. Of all patients, 46 (12.7%) presented symptoms related to helminth infection, predominantly gastrointestinal symptoms (36 patients), as well as fever (9) and asthenia (7). No respiratory or dermatological symptoms were reported. Overall, 135 patients (38.5%) presented eosinophilia. Other infections associated with migration or travel were diagnosed during clinical evaluation, including schistosomiasis (44, 12.1%), tuberculosis infection (41, 11.3%), strongyloidiasis (34, 9.4%), malaria (17, 4.7%), filariasis (17, 4.7%), and Giardia lamblia infection (13, 3.6%). Number of STH infection cases diagnosed per year Regarding diagnosis, 346 cases (95.8%) were confirmed by detection of eggs in a stool microscopic examination, while in the remaining 16 cases, 11 showed hookworm larvae growth and 5 involved observation of adult A. lumbricoides worms in vomitus. Of the 361 patients, 87 were diagnosed with A. lumbricoides infection, 113 with T. trichiura, 126 with hookworm infection, and 35 had multiple helminth infections: 25 cases of co-infection with A. lumbricoides and T. trichiura, 2 cases with A. lumbricoides and hookworms, 6 cases with T. trichiura and hookworms, and 2 cases with all three helminths. When analyzing single-species infections and comparing the three main STH species, we found statistically significant differences in age and sex distribution (Table 3). Hookworm infections occurred in younger patients and showed a higher proportion of males. A. lumbricoides cases were significantly more likely to be travelers (p < 0.05). Hookworm infections showed higher rates of eosinophilia (p < 0.05), whereas T. trichiura showed the highest prevalence of anemia (p < 0.05). No significant differences were observed regarding the presence of symptoms. Table 3Comparison of clinical and epidemiological characteristics of patients with specific STH infectionsClinical and epidemiological characteristicsA. lumbricoides (n = 87)T. trichiura (n = 113)Hookworms (n = 126)p valueMean age, years (SD)33.4 (18.4)33.9 (17.2)28 (13.5) < 0.05Female sex, n (%)37 (42.5)53 (46.9)31 (24.6) < 0.05Travelers, n (%)13 (14.9)2 (1.8)10 (7.9) < 0.05Symptoms, n (%)9 (10.3)15 (13.3)17 (13.5)0.7Eosinophilia, n (%)25 (28.7)30 (26.5)69 (54.7) < 0.05Eosinophil count: cell/μL mean (SD)471 (499)498 (692)908 (955) < 0.05Anemia, n (%)16 (18.4)33 (29.2)10 (7.9) < 0.05Hemoglobin, g/dL mean (SD)15 (1.4)13.4 (1.2)14.5 (1.5)0.2 Comparison of clinical and epidemiological characteristics of patients with specific STH infections A total of 344 patients (95%) received treatment, and only one patient (treated with mebendazole) reported adverse effects, consisting of gastrointestinal discomfort. All patients received benzimidazole-based regimens, and 31 also received ivermectin as part of treatment for concomitant strongyloidiasis. The most frequent regimens were albendazole 400 mg daily for 3 days, albendazole 400 mg single dose, and mebendazole 100 mg every 12 h for 3 days, depending on the helminth species. Cure rates for A. lumbricoides were close to 100% across all regimens. For T. trichiura, albendazole achieved a cure rate of 94%, and mebendazole 92%. Hookworm infections showed the lowest cure rates: 83% for albendazole single dose and 92% for mebendazole (Table 4). Table 4Most commonly used treatment regimens for each STH infection and cure ratesTreatment and follow-upA. lumbricoides (n = 87)T. trichiura (n = 113)Hookworms (n = 126)Patients receiving treatment, n (%)84 (96.5)105 (92.9)120 (95.2)Drug and dosage (n)—Cure rate (%)*ALB-SD (8)–100*ALB-3D (7)–100*MEB-3D (63)–97*ALB-3D (22)–94*MEB-3D (72)–92*ALB-SD (24)–83*ALB-3D (23)–100*MEB-3D (66)–92Post-treatment stool sample performed, n (%)53 (63.1)70 (66.6)86 (71.6)Negative post-treatment result, n (%)52 (98.1)65 (92.9)79 (91.9)Follow-up time in months, median (IQR)1 (1)1 (1)2 (2)ALB-SD Albendazole 400 mg single dose, ALB-3D Albendazole 400 mg daily for 3 days; MEB-3D Mebendazole 100 mg every 12 h for 3 days Most commonly used treatment regimens for each STH infection and cure rates *ALB-SD (8)–100 *ALB-3D (7)–100 *MEB-3D (63)–97 *ALB-3D (22)–94 *MEB-3D (72)–92 *ALB-SD (24)–83 *ALB-3D (23)–100 *MEB-3D (66)–92 ALB-SD Albendazole 400 mg single dose, ALB-3D Albendazole 400 mg daily for 3 days; MEB-3D Mebendazole 100 mg every 12 h for 3 days The interval between treatment and follow-up ranged from 1 to 12 months (median 1 month, IQR 1–3 months). Follow-up stool examination was performed in 231 out of 361 patients (64%). No significant differences were observed between migrants (63.0%), VFR (70.2%) and travelers (57.7%) (p = 0.48). Eighteen patients (7.8%) still had at least one soil-transmitted helminth infection, including five cases with multiple species. Table 5 shows a detailed summary of the initial isolation and treatment, the follow-up stool sample to confirm eradication, and the subsequent treatment administered. Only three of these cases remained positive after the second treatment. In case 7, following a new positive microscopic examination of T. trichiura eggs, a further treatment was given with mebendazole 100 mg every 12 h for 3 days combined with ivermectin at a dose of 200 µg (µg) per kg. In case 14, where hookworm persisted, albendazole was administered at a dose of 400 mg every 12 h for 7 days, and in case 15, where A. lumbricoides was observed, mebendazole 100 mg every 12 h for 3 days was prescribed. In all three cases, a new stool sample was obtained at least 1 month after completing treatment, with negative results in all of them. Table 5Follow-up information of STH infection cases with treatment failureInitial STH infectionTreatmentStool sample resultRe-treatmentStool sample result1T. trichiuraMEB-3DA. lumbricoidesNo2T. trichiura and hookwormALB-3DT. trichiuraNo3HookwormALB-SDHookwormNo4HookwormMEB-3DHookwormNo5A. lumbricoidesMEB-3DA. lumbricoidesALB-3DNegative6T. trichiuraMEB-3DT. trichiuraMEB-3DNegative7T. trichiuraALB-3DT. trichiuraMEB-3DT. trichiura8T. trichiuraMEB-3DT. trichiuraMEB-3DNegative9T. trichiuraMEB-3DT. trichiuraALB-3DNot performed10HookwormALB-SDHookwormMEB-3DNot performed11HookwormMEB-3DHookwormALB-3DNegative12HookwormALB-SDHookwormALB-3DNot performed13HookwormMEB-3DHookwormALB-7DNot performed14HookwormMEB-3DHookwormALB-3DHookworm15A. lumbricoides and hookwormMEB-3DA. lumbricoides and hookwormALB-SDA. lumbricoides16A. lumbricoides and T. trichiuraALB-SDA. lumbricoidesMEB-3DNot performed17A. lumbricoides and T. trichiuraMEB-3DT. trichiuraALB-3DNot performed18A. lumbricoides and T. trichiuraMEB-3DT. trichiuraALB-7DNot performedALB-SD Albendazole 400 mg single dose, ALB-3D Albendazole 400 mg daily for 3 days, ALB-7D Albendazole 400 mg every 12 h for 7 days, MEB-3D Mebendazole 100 mg every 12 h for 3 days Follow-up information of STH infection cases with treatment failure ALB-SD Albendazole 400 mg single dose, ALB-3D Albendazole 400 mg daily for 3 days, ALB-7D Albendazole 400 mg every 12 h for 7 days, MEB-3D Mebendazole 100 mg every 12 h for 3 days Discussion This study described cases of soil-transmitted helminth infections managed by the International Health Unit Vall d’Hebron-Drassanes in Barcelona from 2014 to October 2024. Most diagnosed cases involved migrants or VFR, with a mean age of 32 years and a predominance of males. Patients generally originated from low- or middle-income countries, consistent with the usual distribution of STH infections [4, 8]. The majority of cases came from Sub-Saharan Africa, particularly Equatorial Guinea, which accounted for nearly half of the cases from that region. This likely reflects the high migratory flow between the two countries due to their post-colonial ties. Studies on imported STH infections conducted in southern Madrid [8] and Almería [9, 10] reported similar findings, with a high proportion of patients originating from Sub-Saharan Africa. Notably, only 7.2% of diagnoses were among travelers, suggesting that this condition is uncommon in this group. Among travelers, no single continent showed marked prevalence, with cases distributed uniformly across Africa, South America, and Asia. The mean duration of travel was prolonged, suggesting long-term travel, such as backpacking or cooperation, may be a risk factor for STH exposure and infection. Regarding the number of cases diagnosed per year, a progressive increase was observed until 2019, reaching 52 cases annually, followed by a marked decrease in 2020 and persistently low values in subsequent years. This sharp decline was likely related to the COVID-19 pandemic, which not only reduced migratory flows but also led to prioritization of healthcare for individuals affected by SARS-CoV-2, limiting care for other medical conditions. Another possible explanation for the decrease in cases is the implementation of Mass Drug Administration (MDA) programs. Since the early 2010 s, these programs have been expanded globally under WHO strategies, with substantial increases in preventive chemotherapy coverage. MDA has been shown to reduce both the prevalence and intensity of infection, particularly in endemic regions, contributing to a sustained decline in STH burden over time. This effect may partly explain the relatively low prevalence observed even after the recovery of migratory flows following the COVID-19 pandemic [11, 12]. Only 46 patients presented symptoms, all of which were mild, and none exhibited respiratory manifestations. To attribute symptoms to STH infections, cases in which patients had another infectious condition that could explain the symptoms were excluded. Nevertheless, the nonspecific nature of symptoms and the lack of a clear temporal correlation between infection, symptom onset, and resolution after treatment make it difficult to establish a direct link between infection and clinical presentation. However, this finding underscores the importance of systematic screening in international health, particularly among migrant populations. As part of the screening for imported diseases among migrants, additional diagnoses included schistosomiasis (12.1% of cases), tuberculosis infection (11.3%), and Strongyloides stercoralis infection (9.4%). This latter parasite is of particular interest in the context of this study, as its treatment (ivermectin) also has activity against STH infections. Although ivermectin is generally reserved for second-line therapy [4], the increasing reports of treatment failure with benzimidazoles in recent years, particularly for T. trichiura, may confer a more prominent role to ivermectin [2, 13]. Globally, A. lumbricoides is considered the most prevalent STH species; however, in this study, more cases of T. trichiura and hookworm were diagnosed (35% and 39%, respectively, compared to 26% for A. lumbricoides, excluding cases with multiple species). A meta-analysis conducted in 2015, compiling data on helminth infections in Spain between 1990 and 2015 [10], reported similar findings, with hookworm being the most prevalent, followed by T. trichiura and A. lumbricoides. The use of albendazole and ivermectin as part of MDA programs has proven highly effective in eradicating STH infections [11, 14]. Furthermore, single-dose albendazole is considered an effective treatment for A. lumbricoides [15]. The lower number of A. lumbricoides cases observed in this study may be explained by prior participation of many individuals in MDA programs that included albendazole. Treatment decisions were made by the attending physicians based on their clinical experience. For patients receiving single-dose albendazole, the medication was administered under direct observation following a point-of-care dispensing strategy. In cases requiring multiple doses over several days, medication was provided for self-administration. However, we acknowledge a potential bias favoring single-dose regimens to ensure adherence. More than 60% of treated patients underwent a follow-up stool microscopic examination, frequently 1 month after completing therapy. For A. lumbricoides, eradication rates approached 100% across all regimens. For hookworm, single-dose albendazole showed cure rates below 90%, whereas 3-day courses of albendazole or mebendazole achieved better results. For T. trichiura, where limited efficacy of single-dose benzimidazoles has been documented [16], 3-day regimens of albendazole or mebendazole achieved cure rates slightly above 90%. The reduced efficacy of benzimidazoles against T. trichiura has emerged over the past two decades. Although resistance mechanisms remain unclear, single-nucleotide polymorphisms (SNPs) have been reported in zoonotic helminths, raising the hypothesis that similar mutations may occur in STH species [2]. Consequently, recent studies have evaluated ivermectin in combination with benzimidazoles as first-line therapy for STH infections, particularly T. trichiura [15–18]. Given their different mechanisms of action, the risk of developing new resistance pathways is considered low [10]. In this study, 18 of the 231 post-treatment stool examinations showed persistent STH infection, as detailed in Table 5. Notably, while 9.6% of patients initially presented with co-infection (35 of 361), this proportion increased to 22.2% among those with treatment failure (4 of 18), suggesting that polyparasitism may contribute to therapeutic failure. Polyparasitism with multiple helminth species is common in endemic settings and may influence host immune responses and infection dynamics. However, its impact on treatment outcomes remains complex and not fully established, with heterogeneous findings across studies [19]. Among single-species infections, hookworm accounted for most failures, followed by T. trichiura, while A. lumbricoides had only one case of failure. Subsequent treatments generally involved changing drugs or extending the duration of therapy. In three cases, a third treatment was required due to persistent positive stool results; one of these included a combination of ivermectin and a benzimidazole, with all three ultimately achieving negative follow-up results. The main limitation of this study is related to its retrospective and observational design, as well as the characteristics of the study population, primarily migrants with limited access to healthcare and high mobility. For many patients, baseline laboratory testing and post-treatment stool examinations could not be performed, as they were often in migration processes that complicated clinical follow-up. This difficulty in follow-up may also have contributed to variability in the interval between treatment and subsequent follow-up stool examination, potentially shortening the time required for egg clearance and misclassifying some cases as treatment failures. Conversely, longer intervals may introduce a different source of bias, as delayed assessments could increase the likelihood of reinfection, particularly among frequently exposed individuals, such as travelers or VFR patients. In addition, treatment regimens were prescribed by different clinicians, likely favoring point-of-care dispensing strategies and single-dose regimens to ensure adherence, which introduce variability in dosing and complicate standardization. Data were collected from 2014 to 2024, during which therapeutic trends and prescribing practices may have evolved. It should also be noted that cases were drawn from a clinical registry of patients seen at our center, but we cannot confirm whether all individuals diagnosed with STH infections were included. Conclusions This study provides clinical insight into soil-transmitted helminth infections in a cohort of migrants and travelers in a non-endemic setting. Although a small proportion of patients remained positive after treatment, these findings should be interpreted with caution given the variability in follow-up and the potential influence of multiple factors, including timing of assessment, exposure risk, and co-infections. Further studies are needed to better understand determinants of persistent positivity in this population. Acknowledgements Not applicable. Author contributions Conceptualization: IBB and FS; data curation: IBB, FS, and ES; formal analysis: IBB and FS; investigation: IBB, FS, ES, and IM; methodology: IBB and FS; supervision: IM; writing—original draft: IBB and FS; writing review and editing: IBB, FS, ES, NSD, JMC, MLA, PBN, DP, SMSJV, IOS, and IM. All authors read and approved the final manuscript. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Data availability Data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate The protocol for this study was approved by the Clinical Research Ethics Committee of Vall d’Hebron University Hospital (PR(AG) 222-2025). A waiver of written informed consent was warranted considering the retrospective nature of the study and the expected large number of records to be screened. Consent for publication Not applicable. Competing interests The authors declare no competing interest. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data that support the findings of this study are available from the corresponding author upon reasonable request.